JPMorgan Chase & Co. Issues Pessimistic Forecast for Agilent Technologies (NYSE:A) Stock Price

Agilent Technologies (NYSE:A) had its target price decreased by JPMorgan Chase & Co. from $165.00 to $160.00 in a note issued to investors on Tuesday,Benzinga reports. The firm currently has an “overweight” rating on the medical research company’s stock. JPMorgan Chase & Co.‘s price target suggests a potential upside of 15.85% from the stock’s current price.

Other equities research analysts have also issued reports about the stock. Citigroup increased their target price on shares of Agilent Technologies from $150.00 to $165.00 and gave the stock a “buy” rating in a report on Thursday, August 22nd. TD Cowen raised their price objective on shares of Agilent Technologies from $153.00 to $160.00 and gave the company a “buy” rating in a research report on Thursday, August 22nd. UBS Group upped their target price on shares of Agilent Technologies from $141.00 to $150.00 and gave the stock a “neutral” rating in a report on Thursday, August 22nd. Bank of America increased their price target on Agilent Technologies from $140.00 to $147.00 and gave the stock a “neutral” rating in a research note on Thursday, August 22nd. Finally, Stifel Nicolaus restated a “buy” rating and issued a $151.00 price objective on shares of Agilent Technologies in a research report on Monday, August 26th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $143.40.

Agilent Technologies Stock Performance

NYSE:A opened at $138.11 on Tuesday. The stock has a 50-day simple moving average of $137.72 and a two-hundred day simple moving average of $137.43. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.37 and a current ratio of 1.78. Agilent Technologies has a 52-week low of $124.10 and a 52-week high of $155.35. The firm has a market capitalization of $39.68 billion, a PE ratio of 31.25, a P/E/G ratio of 5.91 and a beta of 1.07.

Insider Buying and Selling

In other Agilent Technologies news, SVP Dominique Grau sold 9,990 shares of the company’s stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $145.00, for a total transaction of $1,448,550.00. Following the sale, the senior vice president now directly owns 40,011 shares in the company, valued at $5,801,595. This represents a 19.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link.

Hedge Funds Weigh In On Agilent Technologies

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Cetera Investment Advisers grew its holdings in Agilent Technologies by 953.3% during the 1st quarter. Cetera Investment Advisers now owns 32,694 shares of the medical research company’s stock valued at $4,757,000 after purchasing an additional 29,590 shares during the last quarter. iA Global Asset Management Inc. grew its stake in shares of Agilent Technologies by 26.2% during the first quarter. iA Global Asset Management Inc. now owns 21,770 shares of the medical research company’s stock valued at $3,168,000 after buying an additional 4,523 shares during the last quarter. Marshall Financial Group LLC purchased a new stake in shares of Agilent Technologies in the second quarter worth approximately $1,058,000. Van ECK Associates Corp lifted its stake in shares of Agilent Technologies by 6.6% during the 3rd quarter. Van ECK Associates Corp now owns 2,976,905 shares of the medical research company’s stock worth $442,011,000 after acquiring an additional 183,716 shares during the last quarter. Finally, AXA S.A. boosted its holdings in Agilent Technologies by 32.3% during the 2nd quarter. AXA S.A. now owns 362,945 shares of the medical research company’s stock valued at $47,049,000 after acquiring an additional 88,667 shares during the period.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.